187 related articles for article (PubMed ID: 19633103)
1. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
McMurray JJ; Anand IS; Diaz R; Maggioni AP; O'Connor C; Pfeffer MA; Polu KR; Solomon SD; Sun Y; Swedberg K; Tendera M; van Veldhuisen DJ; Wasserman SM; Young JB;
Eur J Heart Fail; 2009 Aug; 11(8):795-801. PubMed ID: 19633103
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anemia with darbepoetin alfa in systolic heart failure.
Swedberg K; Young JB; Anand IS; Cheng S; Desai AS; Diaz R; Maggioni AP; McMurray JJ; O'Connor C; Pfeffer MA; Solomon SD; Sun Y; Tendera M; van Veldhuisen DJ; ;
N Engl J Med; 2013 Mar; 368(13):1210-9. PubMed ID: 23473338
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure.
Klapholz M; Abraham WT; Ghali JK; Ponikowski P; Anker SD; Knusel B; Sun Y; Wasserman SM; van Veldhuisen DJ
Eur J Heart Fail; 2009 Nov; 11(11):1071-7. PubMed ID: 19815661
[TBL] [Abstract][Full Text] [Related]
6. Treatment of anemia with darbepoetin alfa in heart failure.
Abraham WT; Anand IS; Klapholz M; Ponikowski P; Scarlata D; Wasserman SM; van Veldhuisen DJ
Congest Heart Fail; 2010; 16(3):87-95. PubMed ID: 20557327
[TBL] [Abstract][Full Text] [Related]
7. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
[TBL] [Abstract][Full Text] [Related]
8. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).
McMurray JJ; Anand IS; Diaz R; Maggioni AP; O'Connor C; Pfeffer MA; Solomon SD; Tendera M; van Veldhuisen DJ; Albizem M; Cheng S; Scarlata D; Swedberg K; Young JB;
Eur J Heart Fail; 2013 Mar; 15(3):334-41. PubMed ID: 23329651
[TBL] [Abstract][Full Text] [Related]
10. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of anemia in heart failure patients].
Santilli G; Tarantini L; Baio P; Senni M
G Ital Cardiol (Rome); 2011 May; 12(5):319-26. PubMed ID: 21593950
[TBL] [Abstract][Full Text] [Related]
13. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Parissis JT; Kourea K; Panou F; Farmakis D; Paraskevaidis I; Ikonomidis I; Filippatos G; Kremastinos DT
Am Heart J; 2008 Apr; 155(4):751.e1-7. PubMed ID: 18371487
[TBL] [Abstract][Full Text] [Related]
14. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
19. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
[TBL] [Abstract][Full Text] [Related]
20. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
